Developer docs
API playgroundTry for free, no card

Search company profiles

HepGene

Full company profile

uuid002qm8a

Namestring
HepGene
Legal namestring
HepGene
Websiteurl
hepgene.bio
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
liquid biopsy diagnostics, MASLD early detection, metabolic disease screening, non-invasive liver diagnostics, molecular diagnostic testing
Industry4 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAKAEAB
Hepatology & Liver Disease
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeSubscription Recurring
Description

As a liquid biopsy company developing diagnostic technology for MASLD, HepGene is expected to generate revenue through diagnostic testing services, likely as a laboratory-developed test (LDT) or FDA-cleared diagnostic product once their program reaches commercialization.

hepgene.bio
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HepGene is developing a liquid biopsy diagnostic platform for early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). The technology uses blood samples for non-invasive detection of metabolic liver disease at the earliest stages, when quality-of-life preservation interventions are most effective. The programs are currently under development and the company operates as a subsidiary of IVBH.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

HepGene is a liquid biopsy company offering early detection solutions for diseases affecting metabolic health, beginning with metabolic dysfunction-associated steatotic liver disease (MASLD). The company operates under the IVBH parent organization and focuses on quality-of-life preservation at the earliest disease stages. No specific named products, modules, or sub-brandings are detailed in the available source material.

Product and service1 record
1Liquid Biopsy MASLD Diagnostic
CategoryMolecular Diagnostics
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eurofins operates a large network of clinical and specialty diagnostics laboratories worldwide. Its specialty diagnostics arm routinely develops and commercializes biomarker assays, making it a relevant incumbent and potential commercial partner for HepGene.

TypeOthers
Description

Bio-Techne supplies proteins, antibodies, and biomarker assay reagents used by diagnostic developers. While not a direct competitor, it represents the reagent and assay-enabling ecosystem that HepGene's liquid biopsy platform depends on for development and scale-up.

TypeRegional player
Description

Resonance Health provides FerriScan and LiverMultiScan-adjacent MRI-based liver iron and fat quantification, primarily commercialized in Australia/Europe and via clinical trial partnerships. It is a relevant regional non-invasive liver diagnostic comparable.

TypeBroad incumbent
Description

Labcorp is a major clinical lab network with established liver disease and metabolic testing services. It represents both a potential commercial distribution partner and a competitive incumbent in the MASLD diagnostic testing space.

TypeBroad incumbent
Description

Quest Diagnostics is a large clinical reference laboratory offering extensive metabolic and liver-function panels, including specialized MASLD/MASH risk panels. As the likely commercial channel for any LDT-style launch, it is both a potential partner and competitive incumbent.

TypeBroad incumbent
Description

Sonic Healthcare operates clinical laboratories across multiple geographies offering liver and metabolic testing panels. Its global scale makes it a relevant comparator for how specialized liver diagnostic tests reach market via reference lab channels.

TypeDirect peer
Description

Genfit develops diagnostics and therapeutics for NASH/MASLD, including biomarker programs historically partnered with major lab companies. Its deep domain focus on MASLD overlaps directly with HepGene's indication and biomarker thesis.

8Echosens
TypeDirect peer
Description

Echosens manufactures FibroScan, the leading non-invasive point-of-care device for liver fibrosis and steatosis assessment. It is the most established non-invasive alternative to liver biopsy in MASLD/MASH, making it the closest direct competitor to HepGene's liquid biopsy approach.

TypeEmerging player
Description

SomaLogic operates a large-scale proteomics platform that has been applied to MASLD biomarker discovery and risk stratification. As an emerging proteomic biomarker competitor, it is highly relevant to HepGene's blood-based biomarker thesis for metabolic liver disease.

TypeDirect peer
Description

Perspectum offers LiverMultiScan, an MRI-based quantitative liver assessment used in MASLD/MASH clinical trials and practice. As another non-invasive, non-biopsy diagnostic for metabolic liver disease, it competes head-to-head for the same clinical workflow HepGene targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HepGene

Molecular Diagnosticshepgene.bio

HepGene firmographics

Firmographics
Name
HepGene
Legal name
HepGene
Website
https://hepgene.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

HepGene industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAKAEAB
Hepatology & Liver Disease

Keywords

  • Liquid biopsy diagnostics
  • MASLD early detection
  • Metabolic disease screening
  • Non-invasive liver diagnostics
  • Molecular diagnostic testing

HepGene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Diagnostic Testing Services: As a liquid biopsy company developing diagnostic technology for MASLD, HepGene is expected to generate revenue through diagnostic testing services, likely as a laboratory-developed test (LDT) or FDA-cleared diagnostic product once their program reaches commercialization.

Go-to-market motion1 record

Marketing channels1 record

HepGene product offering

Product offering

Core offering

HepGene is developing a liquid biopsy diagnostic platform for early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). The technology uses blood samples for non-invasive detection of metabolic liver disease at the earliest stages, when quality-of-life preservation interventions are most effective. The programs are currently under development and the company operates as a subsidiary of IVBH.

Product overview

HepGene is a liquid biopsy company offering early detection solutions for diseases affecting metabolic health, beginning with metabolic dysfunction-associated steatotic liver disease (MASLD). The company operates under the IVBH parent organization and focuses on quality-of-life preservation at the earliest disease stages. No specific named products, modules, or sub-brandings are detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

  • Liquid Biopsy MASLD Diagnostic

Companies that use HepGene

Customer profile

Segments1 record

Ideal customer profiles1 record

HepGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

HepGene partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

HepGene competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Eurofins operates a large network of clinical and specialty diagnostics laboratories worldwide. Its specialty diagnostics arm routinely develops and commercializes biomarker assays, making it a relevant incumbent and potential commercial partner for HepGene.
  • Laboratory Corporation of America (Labcorp): Labcorp is a major clinical lab network with established liver disease and metabolic testing services. It represents both a potential commercial distribution partner and a competitive incumbent in the MASLD diagnostic testing space.
  • Quest Diagnostics: Quest Diagnostics is a large clinical reference laboratory offering extensive metabolic and liver-function panels, including specialized MASLD/MASH risk panels. As the likely commercial channel for any LDT-style launch, it is both a potential partner and competitive incumbent.
  • Sonic Healthcare: Sonic Healthcare operates clinical laboratories across multiple geographies offering liver and metabolic testing panels. Its global scale makes it a relevant comparator for how specialized liver diagnostic tests reach market via reference lab channels.

Others

  • Bio-Techne: Bio-Techne supplies proteins, antibodies, and biomarker assay reagents used by diagnostic developers. While not a direct competitor, it represents the reagent and assay-enabling ecosystem that HepGene's liquid biopsy platform depends on for development and scale-up.

Regional players

  • Resonance Health: Resonance Health provides FerriScan and LiverMultiScan-adjacent MRI-based liver iron and fat quantification, primarily commercialized in Australia/Europe and via clinical trial partnerships. It is a relevant regional non-invasive liver diagnostic comparable.

Direct peers

  • Genfit: Genfit develops diagnostics and therapeutics for NASH/MASLD, including biomarker programs historically partnered with major lab companies. Its deep domain focus on MASLD overlaps directly with HepGene's indication and biomarker thesis.
  • Echosens: Echosens manufactures FibroScan, the leading non-invasive point-of-care device for liver fibrosis and steatosis assessment. It is the most established non-invasive alternative to liver biopsy in MASLD/MASH, making it the closest direct competitor to HepGene's liquid biopsy approach.
  • Perspectum: Perspectum offers LiverMultiScan, an MRI-based quantitative liver assessment used in MASLD/MASH clinical trials and practice. As another non-invasive, non-biopsy diagnostic for metabolic liver disease, it competes head-to-head for the same clinical workflow HepGene targets.

Emerging players

  • SomaLogic (now part of Standard BioTools): SomaLogic operates a large-scale proteomics platform that has been applied to MASLD biomarker discovery and risk stratification. As an emerging proteomic biomarker competitor, it is highly relevant to HepGene's blood-based biomarker thesis for metabolic liver disease.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

HepGene social profiles

Digital presence

HepGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HepGene leadership team

Management profile

Number of profiles

HepGene funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HepGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HepGene

What does HepGene do?

HepGene is developing a liquid biopsy diagnostic platform for early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). The technology uses blood samples for non-invasive detection of metabolic liver disease at the earliest stages, when quality-of-life preservation interventions are most effective. The programs are currently under development and the company operates as a subsidiary of IVBH.

Is HepGene a public or private company?

HepGene is a private company. It is classified as corporate owned and is currently operating.

When was HepGene founded?

HepGene was founded in 2020. It employs 1 to 10 people.

How does HepGene make money?

One revenue line is on record: diagnostic Testing Services.

Who are HepGene's main competitors?

Broad incumbents on record are Eurofins Scientific, Laboratory Corporation of America (Labcorp), Quest Diagnostics and Sonic Healthcare. Bio-Techne is listed as an others. Resonance Health is listed as a regional player. Direct peers are Genfit, Echosens and Perspectum. SomaLogic (now part of Standard BioTools) is listed as an emerging player.

Does HepGene have an API?

No public API is recorded for HepGene.

What industry is HepGene in?

HepGene's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales